The purpose of this study is to find the safety of combination gene therapy and chemotherapy
in patients with malignant pleural mesothelioma. Pleural catheter will be placed first, then
pts will receive 2 doses of intrapleural vector followed by front line or second line
chemotherapy 4-6 cycles every 21 days.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania